Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v9-FR Version v5-FR
Language French French
Date Updated 2022-06-27 2022-05-30
Drug Identification Number 02430827 02430827
Brand name LINEZOLID INJECTION LINEZOLID INJECTION
Common or Proper name LINEZOLID INJECTION LINEZOLID INJECTION
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients LINEZOLID LINEZOLID
Strength(s) 2MG 2MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 300 mL 300 mL
ATC code J01XX J01XX
ATC description OTHER ANTIBACTERIALS OTHER ANTIBACTERIALS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2022-04-30 2022-04-30
Estimated end date 2022-06-24 2022-06-24
Actual end date 2022-06-24
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Fresenius Kabi Canada regrets to advise that due to a production delay, we will be encountering a supply interruption on our Linezolid Injection 2 mg/mL freeflex® Bag 300 mL effective April 30, 2022 until June 24, 2022. Please note that all available inventory expires April 30, 2022. Fresenius Kabi Canada regrets to advise that due to a production delay, we will be encountering a supply interruption on our Linezolid Injection 2 mg/mL freeflex® Bag 300 mL effective April 30, 2022 until June 6, 2022. Please note that all available inventory expires April 30, 2022.
Health Canada comments